Basilea Presents Compelling Clinical and Preclinical Data on its Novel Broad-spectrum Antifungal BAL8557

28-Jun-2006

Basilea Pharmaceutica Ltd. presented data on its antifungal BAL8557 showing a promising safety and drug-drug interaction profile. Additional data confirms broad-spectrum antifungal activity. Basilea presented clinical posters demonstrating a favorable drug-drug interaction profile for BAL8557 and showing BAL8557's broad-spectrum to include difficult to treat pathogens.

Promising Drug-Drug Interaction Profile Hospitalized patients requiring systemic antifungal therapies are often immunocompromised, such as HIV/AIDS, cancer or transplant patients, and receive multi-drug medications capable of producing drug-drug interactions and adverse events. Thus drug-drug interaction and safety profile are important aspects of new antifungal therapies.

The studies show that BAL8557 has a promising drug-drug interaction profile. Ciclosporin and tacrolimus are frequently used and important immunosuppressant drugs in transplant medicine. BAL8557 had no significant impact on the pharmacokinetics of ciclosporin and a relatively modest effect on tacrolimus. In addition, BAL8557 did not affect the kinetics of warfarin, a widely used anticoagulant drug.

Excellent clinical efficacy in Candida esophagitis was published as a late-breaker at the Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2005. The presentation at ISHAM this week highlights in addition the good safety and tolerability profile, and the linear and therefore predictable pharmacokinetics of BAL8557. Furthermore BAL8557 did not show a prolongation of cardiac conductance, often associated with the azole class.

https://www.bionity.com/en/news/55882/basilea-presents-compelling-clinical-and-preclinical-data-on-its-novel-broad-spectrum-antifungal-bal8557.html